The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts
Authors:
- 1 February 2016
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 140 (2) , 270-276
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- The Role of Preexisting Diabetes Mellitus on Incidence and Mortality of Endometrial CancerInternational Journal of Gynecological Cancer, 2013
- Mortality After Incident Cancer in People With and Without Type 2 DiabetesDiabetes Care, 2012
- Diabetes and CancerDiabetes Care, 2010
- The association between metabolic abnormality and endometrial cancer: A large case-control study in ChinaGynecologic Oncology, 2010
- Metformin is a potent inhibitor of endometrial cancer cell proliferation—implications for a novel treatment strategyGynecologic Oncology, 2010
- Does Surgical Quality Improve in the American College of Surgeons National Surgical Quality Improvement ProgramAnnals of Surgery, 2009
- Endometrial cancer and obesity: Epidemiology, biomarkers, prevention and survivorshipGynecologic Oncology, 2009
- Prospective assessment of lymphatic dissemination in endometrial cancer: A paradigm shift in surgical stagingGynecologic Oncology, 2008
- Diabetes and Risk of Endometrial Cancer: A Population-Based Prospective Cohort StudyCancer Epidemiology, Biomarkers & Prevention, 2007
- Obesity, diabetes, and other factors in relation to survival after endometrial cancer diagnosisInternational Journal of Gynecological Cancer, 2007